Variable disease course, depending on size of hematoma, age of the patient, presenting neurologic signs/symptoms, presence of underlying coagulopathy or neoplasm, and associated injuries.
One week of antiepileptic therapy (e.g., phenytoin, levetiracetam) should be considered in all cases of acute and acute-on-chronic subdural hematoma, according to the Brain Trauma Foundation guidelines.
Aggressive reversal of coagulopathy should be accomplished in most patients with a subdural hematoma who are taking anticoagulants.
Surgical therapy is usually indicated for acute or chronic subdural hematomas that are expansile or causing neurologic deficit. Observation may be employed for small, stable subdural hematomas that are not causing neurologic compromise.
Control of elevated intracranial pressure using head-of-bed elevation, analgesics, intubation with anesthetics and sedation, hyperosmolar treatment, external ventricular drainage, barbiturates, or decompression hemicraniectomy may be required.
Treatment complications include early or delayed reaccumulation of subdural hematoma, seizures, vascular injury to cortical veins and arteries or dural sinuses adjacent to the hematoma, strokes, persistent neurologic deficit, coma, and death.
A subdural hematoma is a collection of blood between the dural and arachnoid coverings of the brain. As the volume of the hematoma increases, brain parenchyma is compressed and displaced, and the intracranial pressure may rise and cause herniation. While the presence of subdural hematoma can be inferred by neurologic decline and mechanism of traumatic injury, the diagnosis is typically made radiographically (computed tomography or magnetic resonance imaging).
History and exam
Andrew W. Grande, MD
Assistant Professor of Neurosurgery
University of Minnesota
AWG declares that he has no competing interests.
Dr Andrew W. Grande would like to gratefully acknowledge Dr Stephen J. Haines, Dr Praveen R. Baimeedi, Dr Jason S. Hauptma, and Dr Neil A. Martin, previous contributors to this topic. SJH, PRB, JSH, and NAM declare that they have no competing interests.
Nathan J. Ranalli, MD
Department of Neurosurgery
University of Pennsylvania School of Medicine
NJR declares that he has no competing interests.
Marek Ma, MD
Department of Emergency Medicine Administrative Offices
University of Pennsylvania
MM declares that he has no competing interests.
Use of this content is subject to our disclaimer